Concepedia

Publication | Open Access

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial

DOIFull Paper Access

167

Citations

17

References

2008

Year

Changyu Pan, Wenying Yang, Jacqueline Barona, Yiting Wang, Markus Niggli, Pharis Mohideen, Y. Wang, James E. Foley
Diabetic Medicine

Abstract

Vildagliptin is effective and well tolerated in patients with Type 2 diabetes, demonstrating similar glycaemic reductions to acarbose, but with better tolerability.

References

YearCitations

Page 1